Short answer
biote Corp. (BTMD) filed an 8-K current report with the SEC on April 3, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Standard Regulation FD disclaimer language, not substantive business disclosure.
biote Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Standard Regulation FD disclaimer language, not substantive business disclosure
- No investor-actionable operating, financial, strategic, or shareholder information in the provided excerpt
Item EX-99.1 · Exhibit EX-99.1
- 2025 revenue $192.2M, up from $197.2M in 2024; adjusted EBITDA $53.5M, down from $58.2M
- Adjusted EBITDA margin declined to 27.8% from 29.5%, signaling profitability pressure despite capital-light positioning
- 2026 guidance calls for revenue above $190M and adjusted EBITDA above $38M, implying continued earnings uncertainty
- Network exceeded 9,200 certified practitioners and approximately 400,000 active patients as of December 31, 2025
- Share repurchases totaled $25.1M for approximately 5.5M Class V shares, with additional $18.5M paid in January 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other biote Corp. 8-K filings
Get the next BTMD 8-K as it lands
Follow BTMD for push alerts, or ask the research agent what this filing means.